Saccharomyces boulardii plus rifaximin in mesalamine-intolerant ulcerative colitis

Journal of Clinical Gastroenterology

Volumn 44, Issue 5, 2010, Pages 385-

  Guslandi, Mario ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INTERLEUKIN 10; MESALAZINE; PROBIOTIC AGENT; RIFAXIMIN;

DIARRHEA; DISEASE COURSE; DRUG ERUPTION; DRUG FEVER; EVENING DOSAGE; HEPATITIS; HUMAN; LETTER; LIVER TOXICITY; MORNING DOSAGE; NEPHRITIS; PANCREAS FUNCTION; PANCREATITIS; PRIORITY JOURNAL; REMISSION; SACCHAROMYCES BOULARDII; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADULT; ANTI-INFECTIVE AGENTS; COLITIS, ULCERATIVE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PILOT PROJECTS; PROBIOTICS; RIFAMYCINS; SACCHAROMYCES;

EID: 77951730354     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181cb4233     Document Type: Letter

References (5)

1. Marteau P, Nelet F, Le Lu M, et al. Adverse events in patients treated with 5-aminosalicylic acid: 1993 to 1994 pharmacovigilance report for pentasi in France. Aliment Pharmacol Ther. 1996;10: 949-956.
2. Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel disease. Inflamm Bowel Dis. 2008;14: 1585-1596.
3. Dalmasso G, Cottrez F, Imbert V, et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology. 2006;131:1812-1825.
4. Ewashuck JB, Dieleman LA. Probiotics and prebiotics in chronic inflammatory bowel diseases. World J Gastroenterol. 2006;12:5941-5950.
5. Guslandi M, Petrone MC, Testoni PA. Rifaximin for active ulcerative colitis. Inflamm Bowel Dis. 2006;12:335.